AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Avalo Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$11.59+0.32 (+2.84%)

Close on Oct 19, 2026

Market cap: $505.35M
P/E (TTM): –
Dividend yield: –

Avalo Therapeutics, Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Cash & Equivalents	16	135	7.55	13	55	19	3.73	11	2.61	5.20	21	12	3.42	9.52
Short-Term Investments	82	0	–	–	–	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	98	135	7.55	13	55	19	3.73	11	2.61	5.20	21	12	3.42	9.52
Receivables	–	–	–	0	1.06	2.18	1.00	0.82	2.94	0.13	–	–	–	–
Inventory	–	–	0	0.02	0.04	0.00	0.02	0.32	0.38	0	–	–	–	–
Prepaid Expenses & Other	6.91	4.33	0.84	1.29	2.37	2.66	0.71	0.73	0.70	0.39	0.40	0.36	–	–
Total Current Assets	105	139	8.40	16	62	26	18	22	11	5.66	22	12	–	–
Property, Plant & Equipment	–	–	–	–	–	–	1.45	0.59	0.04	0.04	0.04	0.04	–	–
Gross Property, Plant & Equipment	–	–	–	–	–	–	–	0.72	0.15	0.13	0.10	0.08	–	–
Accumulated Depreciation	–	–	–	–	–	–	–	-0.13	-0.11	-0.09	-0.06	-0.04	–	–
Long-Term Investments	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.34	0.74	1.33	1.75	2.00	0.92	0.72	–	–	–	–	–	–	–
Goodwill	11	11	11	14	14	14	14	14	12	0	–	–	–	–
Intangible Assets	–	–	–	0	0.04	1.59	2.43	3.77	18	0	–	–	–	–
Deferred Tax Assets	–	–	–	–	–	–	0	–	–	–	–	–	–	–
Total Assets	116	151	21	33	80	44	36	70	43	5.77	22	12	–	–
Accounts Payable	0.14	0.28	0.45	2.88	3.37	2.57	2.08	1.45	1.30	1.01	0.68	0.93	–	–
Current Portion of Long-Term Debt	–	–	–	–	–	–	–	1.05	0	2.35	3.21	1.91	–	–
Current Debt	–	–	–	–	–	–	–	1.05	0	2.35	3.21	1.91	–	–
Current Portion of Leases	0.39	0.57	0.54	0.53	0.49	0.43	0.16	–	–	–	–	–	–	–
Current Income Taxes Payable	–	–	–	–	0	0	0.55	2.03	2.26	0	–	–	–	–
Deferred Revenue (Current)	–	–	0	0.09	0	–	–	–	0	–	–	–	–	–
Total Current Liabilities	13	6.96	4.62	22	20	15	12	26	11	4.31	5.85	4.99	–	–
Long-Term Debt	–	–	0	13	33	0	–	14	0	0	2.35	5.31	–	–
Long-Term Leases	0.04	0.35	1.37	1.71	2.02	1.04	1.11	–	–	–	–	–	–	–
Operating Lease Liabilities	0.43	0.92	1.90	2.24	2.50	1.46	1.27	–	–	–	–	–	–	–
Deferred Tax Liabilities	0.43	0.27	0.16	0.14	0.11	0.09	0.09	0.07	0.01	0	–	–	–	–
Other Long-Term Liabilities	0.04	0.35	1.37	1.71	2.30	1.88	1.11	0.39	0.02	0	0.37	–	–	–
Total Liabilities	33	18	14	44	57	19	15	49	15	5.56	8.57	10	–	–
Total Debt	–	–	0	13	33	0	–	15	0	2.35	5.56	7.21	–	–
Preferred Stock	–	–	–	–	0	0.00	0.00	0.00	0	0	0	–	–	–
Common Stock	0.02	0.01	0.00	0	0.01	0.08	0.04	0.04	0.03	0.01	0.01	0.00	–	–
Additional Paid-In Capital	531	503	342	293	285	202	135	119	83	70	67	17	–	–
Retained Earnings	-449	-370	-335	-304	-262	-178	-114	-98	-58	-70	-54	-43	–	–
Comprehensive Income & Other	0.07	0	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	83	133	7.30	-11	23	25	21	21	28	0.21	13	-26	-18	-11
Total Equity	83	133	7.30	-11	23	25	21	21	28	0.21	13	-26	-18	-11
Total Liabilities & Equity	116	151	21	33	80	44	36	70	43	5.77	22	12	–	–
Shares Outstanding(shares)	19	10	0.80	0.04	0.04	0.03	0.02	0.01	0.01	0.00	0.00	0.00	–	–
Loans, Net	–	–	–	–	–	–	4.10	–	–	–	–	–	–	–
Deposits	–	–	–	–	–	–	–	–	–	0.05	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -154844.1%
Net margin: -170055.9%
Return on equity, FY2025: -72.4%

Financial strength

Current ratio: 19.31
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 404.1%

Valuation

P/E ratio: –
Price to sales: 8565.22
Price to book: 1.13
Dividend yield: –